158 related articles for article (PubMed ID: 34139284)
1. Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody.
Tian C; Liu J; Zhou H; Li J; Sun C; Zhu W; Yin Y; Li X
Cancer Lett; 2021 Oct; 518():49-58. PubMed ID: 34139284
[TBL] [Abstract][Full Text] [Related]
2. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
4. ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity.
Haines BB; Denslow A; Grzesik P; Lee JS; Farkaly T; Hewett J; Wambua D; Kong L; Behera P; Jacques J; Goshert C; Ball M; Colthart A; Finer MH; Hayes MW; Feau S; Kennedy EM; Lerner L; Quéva C
Cancer Immunol Res; 2021 Mar; 9(3):291-308. PubMed ID: 33355229
[TBL] [Abstract][Full Text] [Related]
5. The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma.
Zhu W; Lv J; Xie X; Tian C; Liu J; Zhou H; Sun C; Li J; Hu Z; Li X
Immunol Lett; 2022 Jan; 241():15-22. PubMed ID: 34774916
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade.
Lin C; Ren W; Luo Y; Li S; Chang Y; Li L; Xiong D; Huang X; Xu Z; Yu Z; Wang Y; Zhang J; Huang C; Xia N
Cancer Immunol Res; 2020 May; 8(5):632-647. PubMed ID: 32127389
[TBL] [Abstract][Full Text] [Related]
7. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy.
Shi Z; Liu B; Huang C; Xie W; Cen Y; Chen L; Liang M
Biochem Biophys Res Commun; 2021 Jun; 559():176-182. PubMed ID: 33945995
[TBL] [Abstract][Full Text] [Related]
8. Improved antitumor effects elicited by an oncolytic HSV-1 expressing a novel B7H3nb/CD3 BsAb.
Zhang Z; Yang N; Lu H; Chen Y; Xu L; Wang Z; Lu Q; Zhong K; Zhu Z; Wang G; Li H; Zheng M; Zhang W; Yang H; Peng X; Zhou L; Tong A
Cancer Lett; 2024 Apr; 588():216760. PubMed ID: 38428724
[TBL] [Abstract][Full Text] [Related]
9. Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses.
Ylösmäki E; Malorzo C; Capasso C; Honkasalo O; Fusciello M; Martins B; Ylösmäki L; Louna A; Feola S; Paavilainen H; Peltonen K; Hukkanen V; Viitala T; Cerullo V
Mol Ther; 2018 Sep; 26(9):2315-2325. PubMed ID: 30005865
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
Vijayakumar G; Palese P; Goff PH
EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.
Jiang H; Rivera-Molina Y; Gomez-Manzano C; Clise-Dwyer K; Bover L; Vence LM; Yuan Y; Lang FF; Toniatti C; Hossain MB; Fueyo J
Cancer Res; 2017 Jul; 77(14):3894-3907. PubMed ID: 28566332
[TBL] [Abstract][Full Text] [Related]
12. Antibody Screening System Using a Herpes Simplex Virus (HSV)-Based Probe To Identify a Novel Target for Receptor-Retargeted Oncolytic HSVs.
Ikeda H; Uchida H; Okubo Y; Shibata T; Sasaki Y; Suzuki T; Hamada-Uematsu M; Hamasaki R; Okuda K; Yamaguchi M; Kojima M; Tanaka M; Hamada H; Tahara H
J Virol; 2021 Apr; 95(9):. PubMed ID: 33627393
[TBL] [Abstract][Full Text] [Related]
13. Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy.
Shi G; Yang Q; Zhang Y; Jiang Q; Lin Y; Yang S; Wang H; Cheng L; Zhang X; Li Y; Wang Q; Liu Y; Wang Q; Zhang H; Su X; Dai L; Liu L; Zhang S; Li J; Li Z; Yang Y; Yu D; Wei Y; Deng H
Mol Ther; 2019 Jan; 27(1):244-260. PubMed ID: 30527756
[TBL] [Abstract][Full Text] [Related]
14. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
[TBL] [Abstract][Full Text] [Related]
15. Folate-conjugated herpes simplex virus for retargeting to tumor cells.
Ye ZQ; Zou CL; Chen HB; Lv QY; Wu RQ; Gu DN
J Gene Med; 2020 Jul; 22(7):e3177. PubMed ID: 32096291
[TBL] [Abstract][Full Text] [Related]
16. Selective Editing of Herpes Simplex Virus 1 Enables Interferon Induction and Viral Replication That Destroy Malignant Cells.
Liu X; He B
J Virol; 2019 Jan; 93(2):. PubMed ID: 30404809
[TBL] [Abstract][Full Text] [Related]
17. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
18. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.
Lemay CG; Rintoul JL; Kus A; Paterson JM; Garcia V; Falls TJ; Ferreira L; Bridle BW; Conrad DP; Tang VA; Diallo JS; Arulanandam R; Le Boeuf F; Garson K; Vanderhyden BC; Stojdl DF; Lichty BD; Atkins HL; Parato KA; Bell JC; Auer RC
Mol Ther; 2012 Sep; 20(9):1791-9. PubMed ID: 22760544
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic herpes simplex virus type 1 (HSV-1) in combination with lenalidomide for plasma cell neoplasms.
Oku M; Ishino R; Uchida S; Imataki O; Sugimoto N; Todo T; Kadowaki N
Br J Haematol; 2021 Jan; 192(2):343-353. PubMed ID: 33216988
[TBL] [Abstract][Full Text] [Related]
20. Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.
Petrovic B; Leoni V; Gatta V; Zaghini A; Vannini A; Campadelli-Fiume G
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
